Clinical Trial Update: A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer [Phase 2]

View source ↗

Summary

Phase 2 study assessing regorafenib as second or third line therapy for metastatic medullary thyroid carcinoma; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medullary Thyroid Carcinoma
• Thyroid Cancer

Drugs mentioned

• Stivarga (regorafenib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Thyroid Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-11-15